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Abstract. The long saphenous vein graft is the com-
monest conduit used for coronary artery bypass surgery.
The short and long term success of the procedure de-
pends on the patency of these bypass grafts. Vein graft
disease can be divided into early (in the first 30 days),
intermediate (1 month to 1 year) and late (over 1 year).
Early graft failure is usually caused by graft thrombosis
and may be related to the surgical procedure, inter-
mediate graft disease results from intimal hyperplasia
while late graft pathology is a consequence of athero-
sclerosis. The etiology and pathological processes lead-
ing to these damaging effects on saphenous vein grafts
are tackled in this review. The loss of endothelial integ-
rity, the phenotypic changes in vascular smooth muscle
cells and involvement of adventitial cells with collabor-
ation of blood borne factors lead to occlusive pathology
of saphenous vein grafts. The accelerated intimal hy-
perplasia and atherosclerosis are characteristic pathobi-
ological features of these vein grafts. Inflammatory and
immunological changes and graft thrombosis are medi-
ated through the secretion and up regulation of growth
factors, pro coagulant substances and other proteins
arising from the vein wall cells and the blood flowing
through them.
Keywords: saphenous vein grafts, vein graft failure,
CABG surgery, intimal hyperplasia, graft atherosclero-
sis, graft thrombosis
1 Introduction
The treatment of coronary artery disease includes a sur-
gical procedure whereby diseased sections of coronary
arteries are bypassed using autologous blood vessels or
grafts. This technique restores the supply of oxygen
and nutrients to match the demands of the myocardium
by improving coronary blood flow. This procedure is
aptly named coronary artery bypass graft (CABG) sur-
Figure 1: A diagram showing a saphenous vein graft (SVG)
anastomosed end to side to the left anterior descending artery
(LAD) and to the aorta to bypass a lesion in the proximal segment
of the LAD. (Modified from Wikipedia)
gery. Segments of the long saphenous vein are harves-
ted and then joined to the coronary artery beyond the
stenotic lesions [coronary artery-saphenous vein graft
(SVG) anastomosis] and to the aorta (aorto-SVG ana-
stomosis) both in an end to side manner (Fig. 1). The
success of this bypass depends on the size of the coronary
artery, the run-off of blood distal to the graft insertion,
the rheology of the blood it contains and the biological
characteristics of the conduit itself. Apart from the long
saphenous vein, the internal thoracic artery, radial arter-
ies and occasionally the gastroepiploic artery, the short
saphenous vein and the arm veins are used to provide
the conduit. However, the long saphenous vein graft
is still the commonest conduit used in coronary artery
bypass graft surgery and the bypass operation for peri-
pheral vascular disease (Allen et al., 2005).
Graft failure results from reduction of graft patency
and studies have shown that this patency is directly re-
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lated to the clinical and prognostic outcome of the pa-
tients (Halabi et al., 2005; Lopes et al., 2012). Various
pathophysiological processes lead to early, intermediate
and late SVG disease with consequent stenosis or occlu-
sion of the conduit. Early graft failure, occurring in the
first 30 days following operation, happens in 8–18% of
vein grafts, usually results from technical problems re-
lated to the surgery and is mainly caused by graft throm-
bosis (Fig. 2) (G. M. Fitzgibbon et al., 1996; Chesebro
et al., 1982). Intermediate graft failure takes place from
1 month to 12 months after CABG, has an incidence of
10% and is the result of SVG intimal hyperplasia (Bour-
assa, Campeau, Lesperance & Grondin, 1982; Sharma,
Khuri & Folland, 1982; S. Goldman et al., 2004). Late
graft failure (Fig. 3) occurs after 1 year and is the res-
ult of ensuing graft atherosclerosis. 25% to 35% of graft
would have failed at 5 years (Hess et al., 2014; Campeau
et al., 1983) and over 50% at 10 years (Kim, Marhefka,
Ruggiero, Adams & Whellan, 2013; C. M. Grondin &
Thornton, 1995; Campeau et al., 1983; G. M. Fitzgib-
bon et al., 1996; S. Goldman et al., 2004).
Figure 2: Early graft failure in saphenous vein graft occluded by
thrombus (t) in its lumen. (H&E; X12.5 magnification).
2 Early Changes in Saphenous Vein
Grafts
Changes in the saphenous vein begin at the time of
harvesting, surgical preparation of the vessel and its
transplantation into the arterial system. Studies on
vein grafts recovered early following bypass graft sur-
gery show that polymorphonuclear (PMN) infiltration
into the intima, media and adventitia occurs in the first
hours after surgery. This infiltration is an early phe-
nomenon and by 7 to 10 days after bypass graft surgery
PMN are virtually absent from the vein graft (Kockx,
Cambier, Bortier, De Meyer & Van Cauwelaert, 1992).
By 24 hours, most endothelial cells have been denuded
Figure 3: Late graft failure in saphenous vein graft showing
intimal hyperplasia (i) and plaque (p) with severe narrowing of
the graft lumen (l). (H&E; X 12.5 magnification).
or sloughed (Kockx et al., 1992). Endothelial cell loss
may be partly related to injury during surgical prepar-
ation of the SV (Gurkan et al., 2014; Angelini, Pas-
sani, Breckenridge & Newby, 1987; Angelini, Christie,
Bryan & Lewis, 1989). Kockx et al. (1992) suggest that
the cause of endothelial denudation is the PMN infiltra-
tion however this infiltration could well be the result of
chemotactic factors released by damaged endothelium
(C. M. Grondin & Thornton, 1995). A recent study by
Schlitt et al. (2006) showed that thrombin and mech-
anical or pharmacological dilatation of human saphen-
ous vein grafts led to increased selectin-mediated PMN
adhesion on vascular endothelium with subsequent en-
dothelial dysfunction. Also Chello et al. (2003) showed
that substantial distention pressure leads to the expres-
sion of endothelial adhesion molecules in human saphen-
ous vein and these in turn cause adhesion of PMNs to
the vein wall. High distension pressure leads to en-
dothelial cell separation, causes disruption of the smooth
muscle cells in the media (Brindle, 1993) and as soon as
there is blood flow the endothelial cells easily wash away
leading to possible vasoconstriction. The denuded sec-
tions will then be covered with new endothelium 1 to 2
weeks after implantation (Hausmann, Merker & Hetzer,
1996). The denudation of endothelium may induce a
cascade mechanism for intimal formation and thicken-
ing and this is supported by studies showing that early
re-endothelialisation inhibits subsequent intimal thick-
ening in vein grafts (Shiokawa, Rahman, Ishii & Sueishi,
1989; Krijnen et al., 2012). In this acute phase there is
also intimal oedema, with deposition of fibrin and plate-
lets onto the endothelium (C. M. Grondin & Thornton,
1995; Chiu & Chien, 2011). Muscle necrosis occurs in
the media, which is more marked in its inner circular
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smooth muscle layer (Kockx et al., 1992; O’Brien et
al., 1998; Cristian et al., 2016). It is suggested that
this may occur from medial ischaemia following inter-
ruption of the venous vasa vasorum (Brody, Angell &
Kosek, 1972) and from direct surgical trauma to the me-
dia with induction of an inflammatory response and cell
necrosis (Hoch, Stark & Turnispeed, 1995; Mannion et
al., 1998; Cristian et al., 2016). Programmed cell death
(apoptosis) has also been noted after arterial injury and
vein grafting (Kockx et al., 1994; Pearlman, Maillard,
Krasinski & Walsh, 1997; O’Brien et al., 1998). The
remaining smooth muscle cells in the graft media are of
the synthetic phenotype (Kockx et al., 1992) in which
state they would respond to various mitogens in contrast
to the contractile phenotype, which do not (Thyberg &
Fredholm, 1987; Brody, Kosek & Angell, 1972). Growth
factors released by the damaged endothelium or injured
smooth muscle cells promote platelet aggregation, hy-
perplasia and the migration of the synthetic smooth
muscle cells to the intima resulting into intimal thick-
ening (Brody, Kosek & Angell, 1972; Groves, Kinlough-
Rathbone, Richardson, Moore & Mustard, 1979; Pack-
ham & Mustard, 1986). PMN, monocytes, lymphocytes
and platelets attach to the freely accessible collagen or
elastic fibres in the basement membrane (Reidy, 1985).
Surgical dissection has been shown to activate adventi-
tial fibroblasts (O’Brien et al., 1997), which in turn
migrate through the media to take part in neointimal
formation in vein grafts (Shi, O’Brien, Ala-Kokko et al.,
1997). This active role of fibroblasts in vascular remod-
elling is also supported by evidence that extracellular
matrix production of the injured adventitia occurs at
the same time as neointimal formation (Shi, O’Brien,
Mannion et al., 1997).
3 Intermediate and late changes in
saphenous vein grafts
3.1 Changes occurring four weeks to one year
The endothelium regenerates after 2 weeks to cover a
much thicker intima (Fuchs, Mitchener & Hagen, 1978;
Hausmann et al., 1996). Fibrointimal hyperplasia de-
scribes the more chronic effects of intimal thickening
commencing 1 month after grafting (Barboriak, Pintar
& Korns, 1974; Unni et al., 1974; Bulkley & Hutchins,
1977; Kalan & Roberts, 1990). This represents regener-
ation of the intimal layer, which consists of a thick layer
of matrix rich in mucopolysaccharides containing fibro-
blasts, smooth muscle cells and occasional foam cells
(Unni et al., 1974). There is loss of smooth muscle
cells from the media and some fibrosis rendering the
vein graft rigid (Barboriak et al., 1974; O’Brien et al.,
1998). The lumen of the graft becomes narrower an-
giographically (C. Grondin et al., 1974) and by 1 year
its length shortens by about 10% during the first year
causing radiological ‘tenting’ of the distal anastomosis
(C. M. Grondin & Thornton, 1995).
3.2 Changes after one year
After the first postoperative year and up to the fourth
year, histological changes in the vein graft are small and
the lumen to wall thickness ratio stabilises although the
graft media and intima may become more fibrous with
more matrix and fewer nuclei. However during this
period an increase in lipid content and number of foam
cells in the vein wall become evident (Kalan & Roberts,
1990). It is believed that lipid deposition, foam cell
presence and intimal thickening are the precursors or
early signs of atherosclerosis (Bulkley & Hutchins, 1977;
Kalan & Roberts, 1990; Vlodaver & Edwards, 1973).
Although these histological features may appear as early
as 3 months postoperatively (Bulkley & Hutchins, 1977)
and at 1 year angiographically (G. Fitzgibbon, Leach,
Keon, Burton & Kafka, 1986), clinical manifestations of
graft disease appear after 3 years following surgery. The
changes are indistinguishable histologically from arterial
atherosclerosis (Unni et al., 1974; Bulkley & Hutchins,
1977) but in contrast to atherosclerosis in arteries which
has got a life history lasting decades, the disease process
in saphenous vein coronary grafts is accelerated and un-
stable leading to sudden pathological events (Killen et
al., 1998; Lytle et al., 1992).
4 Aetiology of vein graft disease
Early graft occlusion occurs within 30 days of coronary
artery surgery. It has been shown in experimental and
clinical studies that early occlusion is mainly thrombotic
in nature (Badimon, Ip, Badimon & Fuster, 1990) while
late occlusion usually results from intimal hyperplasia
with or without thrombus superimposition and athero-
sclerosis. Thrombosis, intimal hyperplasia and athero-
sclerosis seem to occur at different times but they are
pathophysiologically interlinked in the evolution of vein
graft disease.
4.1 Early vein graft disease and occlusion
The saphenous vein can be damaged during harvesting,
surgical preparation and implantation onto the coron-
ary arteries and aorta. The initial damage to the vein
endothelium and adventitia occurs during harvesting
from the leg and this occurs despite using a ‘no-touch’
technique and very careful dissection (Gottlob, 1977;
Roubos, Rosenfeldt, Richards, Conyers & Davis, 1995;
Kim et al., 2013). Vein dissection, handling of the vein
with surgical instruments and adventitial stripping are
all potentially traumatic. Spasm occurs while the vein
is being excised leading to endothelial damage (Bau-
mann, Catinella, Cunningham & Spencer, 1981; Raja
& Sarang, 2013). Spasm causes endothelial disruption
by reducing the luminal surface area upon which the
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endothelial layer lies and by causing smooth muscle
cell herniation into the endothelial layer or lumen in
a pseudopod-like fashion with subsequent protrusion or
sloughing of endothelial cells. Surgical distension of the
vein with fluid (e.g. heparinised blood or saline) under
pressure to check for any leakages from side branches
is known to injure both endothelial and medial cell lay-
ers as demonstrated in several quantitative morpholo-
gical and biochemical studies (Lo Gerfo, Quist, Can-
telmo & Haudenschild, 1983; Angelini, Breckenridge,
Butchard, Armistead & Middleton, 1985; Roubos et
al., 1995; Galea et al., 1999; Khaleel et al., 2012). En-
dothelial damage leads to decreased production of tis-
sue plasminogen activator (tPA) (Nachman & Silver-
stein, 1993), fibrin accumulation and adherence (Bo-
erboom et al., 1980), platelet aggregation, neutrophil
activation and circulating growth modulation (Reidy,
1992; Verrier & Boyle, 1996; Schlitt et al., 2006), which
may result in thrombosis and may subsequently contrib-
ute to intimal hyperplasia. Exposure of the prothrom-
botic basement membrane and other subendothelial tis-
sues occurs following endothelial damage with the re-
lease of tissue factor (Verrier & Boyle, 1996) and the
activation of the extrinsic pathway of coagulation and
subsequent graft thrombosis. Medial damage leads to
local inflammation with monocyte infiltration. Adher-
ent monocytes that will have entered the vessel wall
change into resident macrophages, which secrete smooth
muscle cell mitogens and may accumulate lipid de-
posits thus contributing to vein graft atheroma. En-
dothelial injury occurs during distension either as a res-
ult of direct mechanical trauma or wall tension (Gottlob,
1977; Angelini, Passani et al., 1987; Lo Gerfo, Quist,
Crawshaw & Haudenschild, 1981; Stigler et al., 2012;
Dong Li et al., 2014). Vein distension induces phos-
phorylation of p38 mitogen-activated protein kinase
(Cornelissen, Armstrong & Holt, 2004). The acute loss
of endothelial-independent function that occurs in de-
endothelized saphenous veins with direct effect on the
VSMC, may be due to the p38 mitogen-activated pro-
tein kinase–mediated degradation of the α-actin fila-
ment in venous smooth muscle (J. Goldman, Zhong &
Liu, 2003). The smooth muscle cells of the vein graft
dedifferentiate from their contractile activity with con-
sequent increases in matrix metalloprotease activity and
expression of cytoskeleton-associated proteins, enabling
migration and proliferation of the smooth muscle cells
(J. L. Johnson, van Eys, Angelini & George, 2001). The
storage of the vein in a solution of low oncotic pressure
(e.g. normal saline, Hartmann’s solution, heparinized
saline solution) also causes endothelial injury (Zerkowski
et al., 1993; Osgood et al., 2014; Wise et al., 2015). The
damage to the endothelium reduces the production of
prostacyclin (Angelini, Breckenridge, Psaila et al., 1987)
and endothelium-derived relaxing factor (Angelini et al.,
1989) both of which normally oppose platelet activation
(Radomski, Palmer & Moncada, 1987). Angelini and
others showed reduction of short-term patency with en-
dothelial damage and promotion of platelet and leuko-
cyte adhesion in a pig arteriovenous bypass graft model
(Angelini, Bryan, Williams, Morgan & Newby, 1990).
Other causes for early occlusion of vein grafts include
kinking, technical error in proximal and distal anastom-
osis and sudden exposure of vein graft to high-pressure
pulsatile arterial system. Technical errors during sutur-
ing may result in obliteration, narrowing, artery wall
dissection and tearing of the coronary artery leading
to thrombosis and early graft occlusion at the site of
the distal anastomosis. Early occlusion from thrombosis
is more likely following endarterectomy of the coronary
artery where the intima and inner portion of the media
are shelled out to increase the diameter of the lumen ren-
dering the distal anastomosis possible. This procedure
denudes the endothelium and parts of the media leaving
behind a highly thrombogenic surface which is known to
promote early graft thrombosis (Walley, Byard & Keon
W.J., 1991; Poston et al., 2006). Atherosclerotic disease
at the anastomotic site and poor run-off of blood in the
coronary artery distal to the anastomosis also predispose
to early graft occlusion (Rasmussen et al., 1997).
4.1.1 Graft thrombosis
Vein graft thrombosis follows the pathological process
of Virchow’s triad namely changes in blood flow, al-
terations in blood rheology and changes in the vessel
wall. Decrease of blood flow occurs at kink sites of
vein grafts, or narrowed parts of vein from tight lig-
atures or distorted anastomoses to the coronaries and
the aorta. Early thrombotic occlusion of vein grafts oc-
curs most commonly at these sites. Thrombosis also
occurs on vein lumen denuded from endothelium during
surgical preparation, leaving the blood in contact with
subendothelial collagen, binding and initiating platelet
activation (Baumgartner, Muggli, Tschopp & Turitto,
1976). Cardiopulmonary bypass and major surgery al-
ter blood rheology, which may predispose to thombo-
genicity (Lowe, 1987; Hsu, 1997; Galea, Rebuck, Finn,
Manche` & Moat, 1998). CABG surgery alters circu-
lating levels of the coagulation factors with a marked
perioperative elevation of plasma fibrinogen favouring a
prothrombotic response (Moor et al., 1994; Mannucci
et al., 1995).
4.2 The endothelium and graft thrombosis
The vascular endothelium is a key participant in sev-
eral processes such as coagulation, fibrinolysis, mem-
brane permeability regulation, lipid transport, vasomo-
tor tone, inflammation and the sustenance or altera-
tion of vessel wall structure. The endothelium pro-
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duces and secretes proteins which regulate these pro-
cesses; increases or decreases vascular tone, promotes
coagulation or fibrinolysis, enhances or inhibits plate-
let and leucocyte adhesion or causes structural changes
in the vessel wall through the release of growth factors
and matrix proteins (Lu¨scher, Tanner, Tschundi &
Noll, 1993; Crossman, Carr, Tuddenham, Pearson &
McVey, 1990; Harlan, 1985). The intact endothelium
is anti-thrombotic and anti-coagulant under basal con-
ditions and this is achieved through various processes
to inhibit coagulation and promote fibrinolysis most
markedly NO secretion and the expression of eNOS
(Lu¨scher, Landmesser, von Eckardstein & Fogelman,
2014). The endothelial cells contribute several com-
ponents of the coagulation cascade. The saphenous
vein graft endothelium can be affected by local injur-
ious stimuli (shear stress, surgical injury, hypoxia and
cytokines) or by systemic inflammatory processes such
as endotoxins and cytokines produced by cardiopul-
monary bypass and ischaemia-reperfusion injury (Ver-
rier & Boyle, 1996). Firstly, the endothelial cell does
not constitutively express tissue factor (Drake, Morris-
sey & Edgington, 1989; Crossman et al., 1990). Tis-
sue factor is a 47-kDa membrane bound glycoprotein
co-factor which in conjunction with factor VIIa causes
the activation of the extrinsic pathway of coagulation
(Nemerson, 1988) permitting activation of factors IX
and X. Most other cells in the subendothelial layers
constitutively express tissue factor therefore exposure
of these layers following endothelial injury leads to clot
formation at the site of endothelial denudation (Edging-
ton, Ruf, Rehemtulla & Mackman, 1991). Also injurious
stimuli to the endothelium lead to up-regulation of tis-
sue factor by the endothelial cells initiating coagulation
and there is evidence to suggest that the endothelium
supports the coagulation process, whether initiated by
the extrinsic or the intrinsic pathways. Endothelial cells
carry high-affinity receptors for factors IX and X (Hei-
mark & Schwartz, 1983) and in these cells, IXa binding
was potentiated in the presence of factors VIII and X
indicating the facilitatory role of the endothelium in the
coagulation process (Stern, Nawroth, Kisiel, Vehar &
Esmon, 1985). The second endothelial-derived antico-
agulant mechanism involves thrombomodulin. Throm-
bomudulin is a membrane bound anti-thrombotic reg-
ulatory protein synthesised by endothelial cells and is
expressed on the cellular membrane, where it forms a
1:1 complex with thrombin (Dittman & Majerus, 1990;
Esmon & Owen, 1981). This complex activates circu-
lating protein C, which in the presence of its co-factor
protein S, causes inactivation of factors VIIIa and Va
(Esmon, 1987), destroying their pro-coagulant co-factor
activity. The harvesting and preparation of the saphen-
ous vein attenuates the activity of thrombomodulin by
up to 30%, further increasing the procoagulant effect
(Cook et al., 1991). The overall coagulant status of
the cell will then depend upon the relative balances
of tissue factor and thrombomodulin activity and the
endothelium has developed a complex mechanism that
allows it to down-regulate thrombomodulin while up-
regulating tissue factor expression at the same time in
response to surgical injury, cytokines, endotoxin, hyp-
oxia, shear stress and other stimuli (Nawroth, Handley,
Esmon & Stern, 1986; Bevilacqua et al., 1986; Con-
way & Rosenberg, 1988; Moore, Esmon & Esmon, 1989;
Conway, Bach, Rosenberg & Konigsberg, 1989; E. M.
Boyle, Verrier & Spiess, 1996). Another important anti-
coagulant process utilises the potential of the endothe-
lium to express heparin on its surface (Marcum, McK-
enney & Rosenberg, 1984; Colburn & Buonassisi, 1982).
Compared to arteries, the vein media and its poorly de-
veloped internal elastic lamina expresses less heparan
sulphate (Cox, Chiasson & Gotlieb, 1991) leading to a
procoagulant situation. The expression of this antico-
agulant proteoglycan is mediated by increased release
of antithrombin III. Heparin binds to thrombin redu-
cing the cleavage of fibrinogen to fibrin. It has been
suggested that the activation of thrombin, which occurs
on the platelet membrane also occurs on the surface of
endothelial cells (Rodgers & Shuman, 1983). Thrombin
was formed when adding factor Xa and prothrombin
to endothelial cells and this process was inhibited by
anti-factor V antibody. The production of factor V by
the endothelium was substantiated by S35 methionine
studies (Cerveny, Fass & Mann, 1984) confirming that
the abnormal endothelium plays a role in the throm-
bin formation. If any clot is formed the constitutive
endothelial cell expression of tissue plasminogen activ-
ator (tPA) bonds with thrombospondin and the com-
plex catalyses the conversion of plasminogen to plas-
min promoting local lysis of the clot forms (van Hins-
bergh, 1988; Dichek & Quertermous, 1989; Crossman
et al., 1990). However, the injured endothelium upreg-
ulates plasminogen-activator inhibitor-1 (PAI-1), which
also promotes procoagulant effects.
Apoptosis of the endothelial cells may occur in the
vein subjected to the surgical technique and implanted
in an extraneous part of the circulation. Apoptotic en-
dothelial cells were shown to increase tissue factor pro-
coagulant activity and decrease antigenic thrombomod-
ulin, heparan sulphates and tissue factor pathway inhib-
itor levels and their activity. Moreover thrombin form-
ation was also increased in the presence of apoptotic
endothelial cells. The procoagulant effect in these cells
was caused by increased expression of membrane phos-
phatidylserine and the loss of anticoagulant membrane
components (Bombeli, Karsan, Tait & Harlan, 1997).
The final endothelial anticoagulant mechanism is the
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constant local secretion of soluble vasoactive products
such as nitric oxide (Palmer, Ashton & Moncada, 1988;
Lu¨scher et al., 2014), prostacyclin (MacIntyre, Pearson
& Gordon, 1978) and adenosine which maintain vas-
odilation and prevent platelet aggregation and adhesion
(Furlong, Henderson, Lewis & Smith, 1987; Radomski
et al., 1987). Production of nitric oxide and prostacyclin
is lower in veins than in arteries and their production
is further reduced by bypass grafting due to endothelial
cell loss or metabolic dysfunction (Angelini et al., 1989).
Platelet activation stimulates synthesis of thrombox-
ane A2 (Roth, 1986) and release of dense-granule com-
ponents including serotonin and ATP and α-granule
components including platelet-derived growth factor,
platelet factor IV, fibrinogen, fibronectin, von Willeb-
rand factor antigen and β-thromboglobulin (Stenberg
& Bainton, 1986). These agents together promote vaso-
constriction (Lam, Chesebro, Steele, Badimon & Fuster,
1987), further platelet aggregation (Roth 1986) and
hence further thrombin and fibrin generation (Shuman
& Greenburg, 1986). The low fluid shear stress in graf-
ted saphenous veins as compared to arteries, reduces
the shear-dependent release of tPA, NO and prosta-
cyclin (Allaire & Clowes, 1997; Kabirian, Amoabediny,
Haghighipour, Salehi-Nik & Zandieh-Doulabi, 2015).
Surgical technical problems that reduce blood flow
through the graft may increase the risk of thrombosis.
Saphenous veins, especially when denuded of endothe-
lium are very sensitive to circulating vasoconstrictors,
including endothelin-1, which is the most potent of en-
dogenous vasoconstrictors (Ganesh et al., 2016). The
plasma levels of soluble endothelin-1 increases steeply
at the initiation of cardiopulmonary bypass followed by
an additional slower rise during its course (te Velthuis
et al., 1996). The resulting venoconstriction may atten-
uate blood flow through the graft and promote stasis.
Furthermore thrombin has a vasoconstrictor effect in the
saphenous vein (Yang et al., 1997; Gudmundsdo´ttir et
al., 2008).
4.3 Causes of late graft occlusion
Graft occlusion in the first year after implantation is
caused mainly by intimal hyperplasia with superim-
posed thrombosis (Blaas et al., 2016). Experimental
studies suggest that ischaemia, higher intraluminal pres-
sure, and oxygen tension are major causes of fibrous
hyperplasia (Brody, Kosek & Angell, 1972). Intimal
hyperplasia is believed to represent adaptation of the
vein to the trauma of transplantation and although early
papers had suggested that intimal hyperplasia may be
reduced by aspirin (McCann, Hagen & Fuchs, 1980),
this was disproved in later research (Fuster & Chesebro,
1985; Yamaguchi et al., 1991; Landymore, MacAuley &
Manku, 1990, 1992) although other anti-platelet ther-
apy may reduce intimal hyperplasia (Go¨ncu¨ et al., 2010;
Hermann, Weber & Schror, 2002). Smooth cell prolif-
eration continues after re-endothelialisation occurs and
although the endothelium appears morphologically in-
tact there is evidence that it is functionally impaired
(Angelini et al., 1989; Komori, Okadome & Sugimachi,
1991). After the first year of implantation, vein occlu-
sion is caused principally by graft atherosclerosis. In
70 to 85% of patients presenting with unstable angina
(Chen et al., 1996) and myocardial infarction (Douglas,
1994; Chen et al., 1996) following coronary artery by-
pass graft the culprit lesion is atherosclerotic vein graft
stenosis, often with superimposed thrombosis. The ath-
erosclerosis is rapidly progressive (Yahagi et al., 2016).
It has been suggested that this progressive form of ath-
erosclerosis occurring in saphenous vein grafts is either
initiated or promoted by intimal injury to the graft
(Bulkley & Hutchins, 1977; Smith & Geer, 1983) or by
conventional cardiac risk factors particularly hyperlip-
idaemia with lesser effects from smoking and diabetes
(Solymoss, Nadeau, Milette & Campeau, 1988; Neitzel,
Barboriak, Pintar & Quresh, 1986).
4.3.1 Accelerated Intimal hyperplasia (AIH)
Intimal hyperplasia is the accumulation of smooth
muscle cells and extracellular matrix in the intima and
is the major disease phenomenon occurring in the vein
graft between one month and one year after implanta-
tion that eventually reduces the graft lumen and may
have superimposed thrombosis (Zubilewicz, Wronski &
Bourriez, 2001). Intimal hyperplasia has been described
as a chronic structural change in the graft which pro-
cess leads to formation of thickened fibrocellular layer
between the endothelium and the inner elastic lamina
(Dilley, McGeachie & Prendergast, 1988). Various stud-
ies have shown that many veins exhibit mild intimal or
medial fibrosis before grafting (Thiene et al., 1980) and
diffuse intimal hyperplasia develops in all vein grafts
and is unavoidable (Campeau, Lesperance & Bourassa,
1984; Fuchs et al., 1978). It is believed to be part of the
reparative process that takes place in all vessels after
injury (Schwartz, DeBlois & O’Brien, 1995). It can be
found as a diffuse layer spread evenly throughout the
graft or as a focal lesion found anywhere in the graft
(Fuchs et al., 1978) however some studies show a thicker
intimal layer at the anastomosis (De Weese & Green,
1980; Madras, Ward, Johnson & Singh, 1981). The pro-
cess of intimal hyperplasia starts within 24 hours of en-
dothelial injury with medial smooth muscle proliferation
in response to a number of cytokines and growth factors
released from activated endothelial cells, platelets and
macrophages (Holt et al., 1992) with the early involve-
ment of the immediate response gene c-fos (Galea et
al., 1999). Also, NF-κB mediated signalling is central
in gene regulation of numerous cytokines and adhesion
molecules involved in AIH (Hu et al., 2002; Miyake, Aoki
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& Shiraya, 2006). Indeed, proliferation of intima-bound
medial VSMC is pivotal to AIH in vein grafts (Dilley
et al., 1988; Schwartz et al., 1995) and in the develop-
ment of atherosclerosis (Ross, 1986; Stary et al., 1992).
Intimal hyperplasia occurs quite quickly in vein grafts,
angioplasty and transplantation and is termed acceler-
ated intimal hyperplasia.
In the intact media of blood vessels, the major func-
tion of the smooth muscle cell is maintenance of tension
via contraction-relaxation (Stadler, Campbell & Camp-
bell, 1989) and the cells are arranged predominantly in
a circular fashion. In keeping with their function, the
cell cytoplasm contains numerous myofilament bundles
whereas synthetic organelles such as rough endoplasmic
reticulum are few in number and located at the perinuc-
lear region (J. H. Chamley-Campbell, Campbell & Ross,
1981). Phenotypic modulation is an important initial
event in the pathophysiology of intimal proliferation. In
the majority of cases the VSMCs must first modulate
from the contractile state into a synthetic phenotype be-
fore they become secretory and responsive to mitogenic
stimulation (J. H. Chamley-Campbell et al., 1981) and
capable of migration (J. Chamley-Campbell, Campbell
& Ross, 1979; Thyberg, Palmberg, Ksiazek & Sjo¨lund,
1983). Intimal VSMCs have also been shown to ori-
ginate from adventitial fibroblasts, from bone marrow
progenitor cells, pericytes and pre-existing intimal cells
(Shi et al., 1996). The endothelial cell plays a regulat-
ory role in intimal growth through a number of growth-
inhibitory mechanisms therefore endothelial cell loss
during surgical manipulation of the vein modifies these
effects. Once the endothelium is denuded, platelets ad-
here to the vessel wall, spread and degranulate releasing
mitogens such as platelet-derived growth factor (PDGF)
that stimulate the smooth muscle cells to migrate to
the intima. Injured endothelial and smooth muscle cells
secrete other mitogens such as basic fibroblast growth
factor that stimulates proliferation of SMCs in the me-
dia (Clowes, 1991). Plaques of modified smooth muscle
cells have been found in the intima as early as nine
and ten days following grafting (Brody, Angell & Kosek,
1972; Barboriak, Pintar, Van Horn, Batayias & Korns,
1978). Immunocytochemical studies in diseased aor-
tocoronary vein bypass grafts have shown that the ma-
jority of cells within the fibrous intimal thickening in
veins are smooth muscle cells and macrophages were sel-
dom seen as compared to atherosclerotic arterial disease
(Tsukada, Tejima, Amano, Suzuki & Numano, 1988).
The modulated smooth muscle cells continue to pro-
liferate further in the neointima. Later these activ-
ated SMCs synthesise large quantities of elastin, colla-
gen and proteoglycans and Thyberg, Nilsson, Palmberg
and Sjo¨lund (1985) demonstrated that they produce four
to five times the amount of connective tissue compared
to the contractile phenotype with collagen production
being the most florid (Ang, Tachas, Campbell, Bate-
man & Campbell, 1990). This contributes to depos-
ition of the extracellular matrix leading to progressive
increase in intimal fibrosis with reduction in cellularity
(Allaire & Clowes, 1997). The activated SMCs tempor-
arily produce PDGF-like substance, which stimulates in-
timal growth in an autocrine manner (Nilsson, 1987). It
has been shown recently that Polo like kinase 1 (PLK1),
a serine/threonine kinase that regulates cell cycle pro-
gression and mitosis and its expression and activity is
elevated in tissues and cells with high mitotic index
might play a critical role in VSMC mitosis in hyper-
plastic intima of vein grafts (Sur, Swier, Radwan &
Agrawal, 2016). The secretory phenotypic cellular cyto-
plasm contains large amounts of free ribosomes, rough
endoplasmic reticulum and mitochondria but very few
myofilaments (Thyberg et al., 1983). There is a cor-
responding decrease in myosin, tropomyosin and actin
(Kallioniemi, Jaakkola, Nikkari & Nikkari, 1984). Actin
changes its isoform from being mainly smooth muscle
α-actin in the contractile phenotype to β-actin that is
not predominantly a muscle actin (Rubbia & Gabbiani,
1989). This type of synthetic smooth muscle cells have
been described in vein graft intimal thickening (Unni et
al., 1974; Dilley et al., 1988), in atherosclerotic plaques
(Campbell, Black & Campbell, 1989) and foetal blood
cells (Nikkari, Rantala, Pystynen & Nikkari, 1988). His-
tologically these modified smooth muscle cells in the in-
tima are oriented parallel to the long axis of the ves-
sel (Spray & Roberts, 1977; McGeachie, Prendergast &
Morris, 1983). The extracellular space of the intima con-
tains some collagen fibres, also aligned with the direc-
tion of blood flow; some microfibrils, 10 µm in diameter
and rarely elastin (Fuchs et al., 1978; Brody, Angell &
Kosek, 1972). Synthetic SMCs show an increased abil-
ity to bind and ingest lipoproteins in vitro (Campbell,
Reardon, Campbell & Nestel, 1985). Also, vein grafts
incorporate more total lipids than arteries and normal
veins in hyperlipidaemic patients (Lie, Lawrie & Mor-
ris, 1977). The intima of a normal vein is made up of a
single layer of endothelial cells (Rhodin, 1968) and the
presence of intimal smooth muscle cells is regarded as
the first step to intimal hyperplasia. At 2 weeks after
autologous grafting of a vein patch to the rat carotid
artery, the venous intimal smooth muscles cells existed
in various stages of differentiation (Cuevas & Gutierrez
Diaz, 1982) and at 3 weeks the cells had differentiated to
contain many myofilaments, dense bodies, caveolae in-
tracellulares and gap junctions. This apparent matura-
tion of modified smooth muscle cells to form a muscular
intima has also been described by Unni et al. (1974).
In contrast to arterial injury, vein grafts AIH occur
mostly after re-endothelialisation of the vessel (Dilley,
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McGeachie & Tennant, 1992). One explanatory mech-
anism is the transient ischaemia occurring in the vein
from the time of harvesting to reperfusion after implant-
ation in the arterial system. These adverse conditions
induce the formation and secretion of superoxide radic-
als, which promote SMC proliferation and at the same
time depress the endothelial production of antiprolif-
erative agents such as prostacyclin, NO and adenosine
(Holt et al., 1993; Rao & Berk, 1992). Also loss of
the vasa vasorum blood supply in the vein may lead to
ischaemia and fibrosis. The phenotypic modulation in
SMCs appears to be reversible depending on their pro-
liferative state (J. H. Chamley-Campbell et al., 1981;
Stadler et al., 1989). Modulation into the synthetic
state can be inhibited in vitro by a feeder layer of con-
fluent endothelial or contractile SMCs and by heparin
(J. H. Chamley-Campbell et al., 1981). In vein grafts,
SMCs forming intimal hyperplasia modulate back into
the contractile phenotype about 3 months after grafting
(Dilley et al., 1988). The ability of SMCs to change back
into their contractile phenotype seems to depend also on
the length of time the proliferative stimulus was applied
for (J. H. Chamley-Campbell et al., 1981). Cells that
have been in the synthetic phenotype for a considerable
period of time cannot change back to the contractile
phenotype and will remain permanently responsive to
mitogens and hence maintain the stimulus of intimal hy-
perplasia and atherosclerotic plaque formation. When
vein grafts are implanted in the arterial circulation the
vein wall is subjected to increased wall stress, which is
also implicated in the aetiology of AIH. This has been
shown in animal models where increased wall stress was
shown to up regulate vein graft intimal receptors for
VSMC mitogen basic fibroblast growth factor which is
released by injured endothelial and smooth muscle cells
(Nguyen et al., 1994). Vein distension also increases vein
diameter reducing mean blood velocity and decrease in
shear stress. This reduction in shear stress upregu-
lates the production of mitogens such as platelet-derived
growth factor (PDGF), basic fibroblast growth factor
(bFGF) and endothelin 1 and downregulates growth in-
hibitors like transforming growth factor-β and NO, thus
inducing smooth muscle cell proliferation and intimal
hyperplasia (Cox et al., 1991; Allaire & Clowes, 1997;
Mitra, Gangahar & Agrawal, 2006). This increase in
growth factor activity in both low and high shear stress
conditions leads to the supposition that there is an op-
timum shear value below and above which AIH occurs
(Lemson, Tordoir, Daemen & Kitslaar, 2000). Another
mechanism that has been shown to be involved in neoin-
timal formation in a porcine model of saphenous vein
involves the role of perivascular fibroblasts. These fibro-
blasts may infiltrate injured media of arterialised SVGs,
differentiate to myofibroblasts, acquiring alpha-smooth
muscle actin and take part in neointimal formation. The
intima of human saphenous vein grafts, retrieved during
repeat coronary artery bypass surgery exhibits the pro-
file of cytoskeletal proteins resembling myofibroblasts
seen in porcine vein grafts which suggest that this pro-
cess is mimicked in the clinical situation (Shi, O’Brien,
Mannion et al., 1997).
4.3.2 Accelerated Graft atherosclerosis
Atherosclerotic plaque is not detected until one year
after surgery and is rarely observed before the second
or third year after implantation (Atkinson, Forman &
Vaughn, 1985; Solymoss et al., 1988; Kalan & Roberts,
1990). Plaques are observed histologically in 21% of
grafts at a mean of 5 years after operation. The patho-
genesis of atherosclerosis includes impaired lipid meta-
bolism and an improper immune response leading to
chronic inflammation of the artery or vein graft (Weber
& Noels, 2011). The fundamental process of atheroscler-
osis is similar in native coronary arteries and SVGs but
it is rapidly progressive in the latter that is similar to the
accelerated atherosclerosis occurring in chronic trans-
plant rejection. This rapid disease process is possibly
closely related to chronic endothelial injury and dys-
function (Dilley et al., 1992; E. M. Boyle, Lille, Allaire,
Clowes & Verrier, 1997). The atherosclerotic lesions oc-
curring in vein grafts differ morphologically from lesions
arising in arteries. Vein graft atherosclerosis tends to be
diffuse, concentric, and friable with a poorly developed
or absent fibrous cap and little evidence of calcification,
whereas native coronary disease is proximal, focal ec-
centric and non friable with a well developed fibrous
cap and frequent calcification (Lie et al., 1977; Kalan
& Roberts, 1990; Ratliff & Myles, 1989). Histologic-
ally, vein graft atherosclerosis has the foam cells as the
principal or even the only cells in the lesion and they ap-
pear to erode the thickened intima. Consequently, graft
atherosclerosis resembles experimentally induced ather-
osclerosis in animal models rather than fatty streaks and
plaque lesions in human arteries. The presence of these
foam cells and inflammatory cells such as multinucleated
giant cells has led some researchers to propose an im-
munological basis for vein graft atherosclerosis (Ratliff
& Myles, 1989). The evidence for this is firstly because
this form of atherosclerosis is very similar to that occur-
ring in coronary arteries in patients with underlying im-
munological vascular diseases (Ansari, Larson & Bates,
1985; Bulkley & Roberts, 1975), in laboratory anim-
als with experimentally induced immunological vascu-
lar injury (Wissler & Vesselinovitch, 1983; Alexander,
Clarkson & Fulgham, 1985) and in experimental and hu-
man cardiac transplantation (Kottke-Marchant & Rat-
liff, 1988; D. Johnson, Gao, Scroeder & Billingham,
1988). Secondarily, patients undergoing aortocoronary
bypass have been shown to be immunologically stimu-
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lated in the postoperative period (Baker, Cohen, Head,
DeShong & Graeber, 1986; De Scheerder et al., 1986).
Thirdly, atherosclerotic saphenous vein grafts has shown
increased deposition of immunoglobulin (Fitzmaurice &
Ratliff, 1990; Schepers et al., 2006). Lipid metabolism
in the saphenous vein is relatively atherogenic with in-
creased lipid synthesis and uptake (Larson, Hagen &
Fuchs, 1974) and decreased lipolysis (Shafi, Palinski &
Born, 1987). The presence of high levels of LDL choles-
terol and diabetes are independent factors in SVG ather-
osclerosis (Yanagawa et al., 2014). In vivo intravascular
ultrasound studies suggest that the focal compensatory
enlargement observed in atherosclerotic native coron-
ary arteries does not occur in diseased saphenous vein
grafts (Nishioka et al., 1996). Graft atherosclerosis is
otherwise indistinguishable from the native disease but
because of the thin fibrous cap on a lipid-rich lesion
they are more fragile and prone to rapture and throm-
bosis. Apoptosis plays an important role in the devel-
opment of the atherosclerotic plaque mainly through
smooth muscle cell and macrophage death leading to
plaque instability (S. Bjorkerud & Bjorkerud, 1996; Ben-
nett & Boyle, 1998). Oxidised low density lipoproteins
have been shown to induce apoptosis of smooth muscle
cells and macrophages through the modulation of Fas
and bcl-2 protein expression (Li, Yang & Mehta, 1998).
Superimposition of thrombosis on atherosclerotic ves-
sels is a common occurrence and may lead to recur-
rent angina or myocardial infarction after CABG. In
one study over two thirds of resected vein grafts during
coronary reoperations for recurrent symptoms showed
late thrombosis (Solymoss et al., 1988). Thrombosis
and instability of the plaque in vein grafts can occur
through two mechanisms. Plaque macrophages may re-
lease matrix-degrading enzymes that weaken the fibrous
cap (Libby et al., 1996; Finn, Nakano, Narula, Kolodgie
& Virmani, 2010). Foam cells in the diseased saphenous
vein graft possibly release a factor that induces smooth
muscle cell apoptosis in the atherosclerotic intima de-
pleting the plaque of SMCs. This depletion could pro-
mote plaque rapture and thrombosis (Kockx et al., 1996;
Kockx & Herman, 2000; Stoneman & Bennett, 2004;
Libby, 2008). Complement factor C5a has been implic-
ated in plaque rapture in grafts (Wezel et al., 2014).
The understanding of the detailed pathology of the
different stages of SVG disease offers different possible
opportunities for researchers and clinicians to find ways
to counteract this pathological process and improve
short and long term patency of these conduits thus re-
ducing mortality and morbidity from such a common
disorder. Although arterial conduits such as the left in-
ternal mammary has shown better long term patency,
this vessel is mainly used on the left anterior descend-
ing coronary artery which is usually a bigger vessel than
the others with consequent better flow capacity there-
fore comparison is difficult. The long saphenous vein
is still the commonest conduit used in coronary bypass
surgery therefore improvement in its patency rate is es-
sential because it is here to stay.
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